Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A,C Meningococcal Conjugate Vaccine (freeze-dried)
- Development stage
- Unknown
- Lead developer
- 罗益
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A,C Meningococcal Conjugate Vaccine (freeze-dried) is a bivalent conjugate vaccine developed by Wuxi Royal Biological for the prevention of invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A and C. The vaccine is composed of purified capsular polysaccharides from these two serogroups, each chemically conjugated to a carrier protein. This conjugation process converts the polysaccharides from T-cell independent to T-cell dependent antigens, which significantly enhances immunogenicity, particularly in infants and young children, and promotes the development of immunological memory. It is approved in China for the prevention of meningococcal meningitis and septicemia caused by serogroups A and C.
- Other names
- 冻干A、C群脑膜炎球菌结合疫苗meningococcal group A,C conjugate vaccineWuxi Royal Biological AC conjugate vaccineA,C Meningococcal Conjugate Vaccine (freeze-dried)
02
Targets
Neisseria meningitidis group C capsular polysaccharideNmA CPS (Neisseria meningitidis group A capsular polysaccharide)
Beyond the preview
Go deeper on A,C Meningococcal Conjugate Vaccine (freeze-dried).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on A,C Meningococcal Conjugate Vaccine (freeze-dried).